MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
1256.69%
Quick Ratio
1256.69%
Cash Ratio
138.83%
Debt to Asset Ratio
17.03%
Unit: Thousand (K) dollars
Assets Breakdown
    • Marketable securities - short te...
    • Cash and cash equivalents
    • Marketable securities - long ter...
    • Others
Liabilities Breakdown
    • Common shares, no par value unli...
    • Accumulated deficit
    • Additional paid-in capital
    • Others

Balance Sheets
2026-04-30
2026-01-31
2025-10-31
2025-07-31
Cash and cash equivalents
29,827 36,613 50,152 32,623
Marketable securities - short term
228,638 239,335 143,584 169,290
Restricted investments
75 74 79 72
Investment tax credits receivable
822 1,197 927 709
Prepaid and other current assets
10,638 11,997 6,649 8,618
Total current assets
270,000 289,216 201,391 211,312
Marketable securities - long term
26,709 36,601 8,522 23,011
Property and equipment, net
2,335 2,441 2,477 1,879
Operating lease right of use asset
7,105 7,470 7,716 7,969
Other assets
1,375 1,385 1,362 1,379
Total assets
307,524 337,113 221,468 245,550
Accounts payable
1,793 2,435 6,688 2,384
Accrued expenses and other current liabilities
17,212 19,668 15,275 11,117
Operating lease liabilities, current
2,287 2,318 2,014 1,527
Current portion of note payable
193 188 8,002 5,412
Total current liabilities
21,485 24,609 31,979 20,440
Note payable, net of current portion
24,910 24,736 15,324 17,706
Operating lease liabilities, net of current portion
5,961 6,222 6,455 6,732
Liabilities, total
52,356 55,567 53,758 44,878
Common shares, no par value unlimited shares authorized, 66,989,466 and 52,018,658 shares issued and outstanding as of april 30, 2026 and october 31, 2025, respectively
631,995 631,992 513,281 510,164
Additional paid-in capital
56,325 52,180 27,349 25,869
Accumulated other comprehensive loss
-1,141 -842 -888 -1,209
Accumulated deficit
-432,011 -401,784 -372,032 -334,152
Total shareholder's equity
255,168 281,546 167,710 200,672
Total liabilities and shareholders' equity
307,524 337,113 221,468 245,550
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Marketable securities -short term$228,638K Cash and cashequivalents$29,827K Prepaid and othercurrent assets$10,638K Investment tax creditsreceivable$822K Restricted investments$75K Total current assets$270,000K Marketable securities -long term$26,709K Operating lease right ofuse asset$7,105K Property and equipment,net$2,335K Other assets$1,375K Total assets$307,524K Total liabilities andshareholders' equity$307,524K Total shareholder'sequity$255,168K Liabilities, total$52,356K Accumulated deficit-$432,011K Accumulated othercomprehensive loss-$1,141K Common shares, no parvalue unlimited...$631,995K Note payable, net ofcurrent portion$24,910K Total currentliabilities$21,485K Operating leaseliabilities, net of current...$5,961K Additional paid-in capital$56,325K Accrued expenses andother current...$17,212K Operating leaseliabilities, current$2,287K Accounts payable$1,793K Current portion of notepayable$193K

enGene Therapeutics Inc. (ENGNW)

enGene Therapeutics Inc. (ENGNW)